《Table 1A comparison of the conventional drug discovery and development process with those of the CA

《Table 1A comparison of the conventional drug discovery and development process with those of the CA   提示:宽带有限、当前游客访问压缩模式
本系列图表出处文件名:随高清版一同展现
《从药物开发的角度看工程化T细胞疗法》


  1. 获取 高清版本忘记账户?点击这里登录
  1. 下载图表忘记账户?点击这里登录

CD19 is ubiquitously expressed on all stages of B cells except for hematopoietic stem cells(HSCs)and certain plasma cells.It is also expressed on most B lineage leukemia and lymphoma cells[51,55].It is expected that a successful adoptive CART19 transfer will eliminate B lineage malignancies and normal B cells leading to B cell aplasia.As the treatment does not eradicate the vital HSC,and as B cell aplasia is treatable with intravenous immunoglobulin replacement,CD19 is an excellent target for eliminating B lineage malignancies via the adoptive transfer of CAR T cells due to its antibody accessibility,tumor specificity,and non-lethal normal organ tissue distribution[46,56].